Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.
Industry, Sector and Symbol:
- 50 Day Moving Avg: $1.59
- 200 Day Moving Avg: $1.11
- 52 Week Range: $0.66 - $2.75
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.67
- P/E Growth: 0.00
- Return on Equity: -58.00%
- Return on Assets: -47.29%
- Average Volume: 86,277 shs.
- Beta: 1.59
Frequently Asked Questions for Transition Therapeutics (NASDAQ:TTHI)
What is Transition Therapeutics' stock symbol?
Transition Therapeutics trades on the NASDAQ under the ticker symbol "TTHI."
How were Transition Therapeutics' earnings last quarter?
Transition Therapeutics Inc (NASDAQ:TTHI) issued its earnings results on Tuesday, September, 15th. The company reported ($0.31) earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $0.08. View Transition Therapeutics' Earnings History.
Who are some of Transition Therapeutics' key competitors?
Some companies that are related to Transition Therapeutics include Biogen (BIIB), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Abcam Plc (ABC), Anika Therapeutics (ANIK), Myovant Sciences Ltd (MYOV), Syros Pharmaceuticals (SYRS), Sinovac Biotech (SVA), ChemoCentryx (CCXI), Mirna Therapeutics (SYBX), Syndax Pharmaceuticals (SNDX), Strongbridge Biopharma PLC (SBBP), Fortress Biotech (FBIO), Mereo BioPharma Group PLC (MPH), Kamada (KMDA), Kadmon Holdings (KDMN), Vericel Corporation (VCEL) and Peregrine Pharmaceuticals (PPHM).
How do I buy Transition Therapeutics stock?
Shares of Transition Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Transition Therapeutics' stock price today?
MarketBeat Community Rating for Transition Therapeutics (NASDAQ TTHI)MarketBeat's community ratings are surveys of what our community members think about Transition Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Transition Therapeutics stock can currently be purchased for approximately $1.52.
Consensus Ratings for Transition Therapeutics (NASDAQ:TTHI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Transition Therapeutics (NASDAQ:TTHI)
(Data available from 9/19/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/14/2016||Cowen and Company||Reiterated Rating||Hold||N/A|
|4/19/2016||Canaccord Genuity||Reiterated Rating||Hold||N/A|
Earnings History for Transition Therapeutics (NASDAQ:TTHI)Earnings History by Quarter for Transition Therapeutics (NASDAQ TTHI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Transition Therapeutics (NASDAQ:TTHI)
Current Year EPS Consensus Estimate: $-0.33 EPS
Next Year EPS Consensus Estimate: $-0.57 EPS
Dividend History for Transition Therapeutics (NASDAQ:TTHI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Transition Therapeutics (NASDAQ:TTHI)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Transition Therapeutics (NASDAQ:TTHI)
Latest Headlines for Transition Therapeutics (NASDAQ:TTHI)
Transition Therapeutics (TTHI) Chart for Tuesday, September, 19, 2017